Intron Biotechnology Inc. has entered into an official contract with the U.S. Army Combat Capabilities Development Command (DEVCOM) to develop bacteriophages for combating uropathogenic Escherichia coli (UPEC) infections. DEVCOM, a subcommand of the U.S. Army Futures Command, has been working on a project to develop products that address the risk of urinary tract infections (UTIs) among soldiers exposed to austere environments, such as when deployed or undergoing training.